Bristol-Myers Squibb (Singapore) Pte Ltd.

This is a non-interventional post-marketing surveillance study designed to fulfill a post-approval commitment (PAC) to the China FDA (CFDA). The study is focused on the incidence of expected and unexpected drug-related adverse events (AEs) and serious adverse events (SAEs) in routine clinical applications of daclatasvir hydrochloride (DCV)-based treatment regimens for chronic hepatitis C (CHC) patients. This includes monitoring of the combined treatment regimen of daclatasvir hydrochloride (DCV) and asunaprevir (ASV) soft capsules.

This is a non-interventional post-marketing surveillance study designed to fulfill a post-approval commitment (PAC) to the China FDA (CFDA). The study is focused on the incidence of expected and unexpected drug-related adverse events (AEs) and serious adverse events (SAEs) of daclatasvir hydrochloride (DCV)-based regimens in routine clinical use in patients with chronic hepatitis C (CHC).